Related Experiment Video
Updated: Sep 10, 2026
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents
M J Kelner1, T C McMorris, L Estes
1Department of Pathology, UCSD Medical Center 92103-8320, USA.
Abstract:
The human lung carcinoma cell line MV522 was previously noted to produce extensive metastasis to the lungs, spleen and lymph nodes after subcutaneous transplantation into athymic nude mice. Animals eventually succumb to these metastases, and not primary tumor growth. The ability to produce extensive metastasis after a simple subcutaneous injection in 100% of animals (> 100 tested to date) would be an advantage when screening compounds for anticancer activity. To validate the utility of this xenograft model for testing anticancer agents, we tested the ability of 10 anticancer drugs to either inhibit primary tumor growth and/or prolong life span of MV522-bearing animals. Among the 10 antitumor conventional agents, only mitomycin C and taxol demonstrated primary tumor growth inhibition. Mitomycin C produced a mild increase in median life span of 41% to 63%, while taxol had inconsistent effects. The metastatic MV522 carcinoma model appears to reflect clinical resistance of primary non-small cell lung cancer to conventional chemotherapeutic agents and should be useful for testing new anti-cancer drugs.
Insights
The MV522 lung cancer model effectively mimics human non-small cell lung cancer metastasis and resistance to chemotherapy. This model is valuable for screening novel anticancer drugs and evaluating their efficacy against metastatic disease.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis Research
Background:
- The MV522 human lung carcinoma cell line exhibits extensive metastasis in athymic nude mice.
- Tumor-bearing animals succumb to metastatic disease rather than primary tumor growth.
- A reproducible xenograft model with high metastatic potential is advantageous for anticancer drug screening.
Purpose of the Study:
- To validate the MV522 xenograft model for preclinical anticancer drug testing.
- To assess the efficacy of 10 conventional anticancer agents in inhibiting primary tumor growth and/or prolonging survival.
- To evaluate the model's relevance in reflecting clinical resistance observed in non-small cell lung cancer.
Main Methods:
- Subcutaneous transplantation of MV522 cells into athymic nude mice.
- Administration of 10 different conventional anticancer drugs to tumor-bearing animals.
- Monitoring of primary tumor growth inhibition and animal survival rates.
Main Results:
- Only mitomycin C and paclitaxel (Taxol) demonstrated significant primary tumor growth inhibition.
- Mitomycin C showed a moderate increase in median lifespan (41%–63%).
- Paclitaxel exhibited inconsistent effects on survival.
Conclusions:
- The MV522 metastatic carcinoma model effectively recapitulates clinical resistance of non-small cell lung cancer to conventional chemotherapeutics.
- This model serves as a valuable preclinical tool for evaluating novel anti-cancer drug candidates.
- The model's high success rate in inducing metastasis makes it suitable for drug efficacy screening.
More Related Videos
09:02Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
05:11Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
Published on: May 10, 2024